Clinical trials: Prostatic Diseases
Prostate Cancer
Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC
This study is for patients with cancer of the prostate gland that has metastasized or spread outside the prostate to other parts of the body.
- Trial name
- NCT00327340
- Testing
- custirsen (OGX-011)/mitoxantrone, custirsen (OGX-011)/docetaxel
- Where
- 10 sites in Canada
- Volunteers
- 70 people
- Sponsor
- Achieve Life Sciences
Disease Progression
Treatment Resistance Following Anti-cancer Therapies
The TRANSLATE study aims to better understand why tumors become resistant to standard anti-cancer therapies. New tumor biopsy and blood samples are collected after disease progression on standard-of-care anti-cancer treatment and…
- Trial name
- NCT04436120
- Testing
- De novo tumor tissue biopsy, Research blood draws
- Where
- 33 sites in United States, Argentina and 3 more
- Volunteers
- 38 people
- Sponsor
- Pfizer
Overactive Bladder
Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia
This study will assess the long-term safety of vibegron when dosed up to 52 weeks in men with overactive bladder (OAB) symptoms on pharmacological therapy for Benign Prostatic Hyperplasia (BPH) who previously completed treatment…
- Trial name
- NCT04103450
- Testing
- Vibegron
- Where
- 35 sites in United States, Poland
- Volunteers
- 276 people
- Sponsor
- Urovant Sciences GmbH
Prostate Carcinoma
GET FIT Prostate: A Randomized Controlled Exercise Trial
The GET FIT Prostate trial (Group Exercise Training for Fall prevention and functional Improvements during and after Treatment for Prostate cancer) is a single-blind, parallel group, randomized controlled trial comparing - 1) tai…
- Trial name
- NCT03741335
- Testing
- Resistance Training, Stretching, Tai Chi
- Where
- United States
- Volunteers
- 284 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer
ZD4054 With Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) for Prostate Cancer
The purpose of this research study is to assess the effects of ZD4054 on prostate cancer that has spread to the bones by using new imaging techniques.
- Trial name
- NCT01119118
- Testing
- ZD4054
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Wisconsin, Madison
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy
This pilot phase II trial studies how well giving bevacizumab works in treating patients with relapsed prostate cancer that did not respond to hormone therapy.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer
- Trial name
- NCT01656304
- Testing
- bevacizumab, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Prostate Cancer, Prostate Cancer Metastatic
MSG Use With 18F-DCFPyL PET/CT Imaging
18F-DCFPyL is an agent that binds to prostate specific membrane antigen (PSMA). Due to high levels of PSMA in prostate cancer, treatments targeting PSMA have been developed to deliver therapy to these specific target cells.
- Conditions
- Prostate Cancer, Prostate Cancer Metastatic, Prostatic Neoplasm
- Trial name
- NCT03693742
- Testing
- 18F-DCFPyL PET/CT scan, MSG drink
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00028769
- Testing
- bicalutamide, estramustine, etoposide
- Where
- 91 sites in United States
- Volunteers
- 41 people
- Sponsor
- SWOG Cancer Research Network
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
This phase Ib trial studies the dose and schedule of 177Lu-PSMA-617 and pembrolizumab in treating persons with castration-resistant prostate cancer that has spread to other places in the body.
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma
- Trial name
- NCT03805594
- Testing
- Lutetium Lu 177-PSMA-617, Pembrolizumab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
Phase II Investigation of Prostate Artery Embolization (PAE) Before Radical Prostatectomy in Prostate Cancer Patients
The purpose of this study is to determine whether pre-operative prostate artery embolization (PAE) reduces intra-operative blood loss and improves surgical outcomes among prostate cancer patients undergoing robot-assisted…
- Trial name
- NCT02173522
- Testing
- Prostate artery embolization (PAE)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Shivank Bhatia
Melanoma, Sarcoma
A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen
This was a phase 1, open-label, multiple dose, single-arm study. The mixed bacteria vaccine (MBV) was administered at a starting dose of 250 EU (1 µL) and escalated in each subject to a dose inducing the desired pyrogenic effect…
- Conditions
- Melanoma, Sarcoma, Gastrointestinal Stromal Tumor (GIST), Head and Neck Cancer
- Trial name
- NCT00623831
- Testing
- Mixed bacterial vaccine
- Where
- Germany
- Volunteers
- 17 people
- Sponsor
- Ludwig Institute for Cancer Research
Prostate Cancer
S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
RATIONALE: Monoclonal antibodies, such as anti-IL-6 chimeric monoclonal antibody, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00433446
- Testing
- CNTO 328
- Where
- 123 sites in United States
- Volunteers
- 62 people
- Sponsor
- SWOG Cancer Research Network
Prostate Cancer, Prostate Cancer Adenocarcinoma
Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer
This is a prospective, randomized, open-label, phase II trial of cabozantinib in subjects with untreated, high risk prostate cancer undergoing radical prostatectomy. This multicenter study will enroll 30 subjects.
- Conditions
- Prostate Cancer, Prostate Cancer Adenocarcinoma, Non-Metastatic
- Trial name
- SPARC (NCT03964337)
- Testing
- Cabozantinib, Radical Prostatectomy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Duke University
Prostate Cancer
A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer
This is a study to test the safety and efficacy of an investigational chemotherapy agent in patients with advanced prostate cancer.
- Trial name
- NCT00780975
- Testing
- Aplidin (plitidepsin)
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- PharmaMar
Infection
PReclude Infection EVEnts With No Prophylaxis Transperineal Biopsy
Approximately one million transrectal prostate biopsies are performed annually in the U.S., and the risk of post- biopsy infection is increasing due to greater antibiotic resistance of rectal flora.
- Trial name
- PREVENT (NCT04843566)
- Testing
- Transperineal MRI-guided prostate biopsy, Transrectal MRI-guided prostate biopsy, Antibiotic (prophylaxis)
- Where
- 10 sites in United States
- Volunteers
- 687 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer
A Study of Definitive Therapy to Treat Prostate Cancer
To assess the safety of treating men with oligometastatic prostate cancer with the following therapy: (1st) Systemic chemo-hormonal therapy with up to 6-months (~24 weeks) of neoadjuvant androgen deprivation and up to 6 cycles of…
- Trial name
- oligo-mets (NCT02716974)
- Testing
- Leuprolide Acetate, Bicalutamide, Docetaxel
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostatic Hyperplasia, Benign, Enlarged Prostate With Lower Urinary Tract Symptoms
Prostate Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Investigator-initiated study to evaluate the safety and efficacy of prostate artery embolization for the treatment lower urinary tract symptoms in patients with benign prostatic hyperplasia
- Trial name
- NCT03055624
- Testing
- Embosphere microparticles for prostate artery embolization
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of California, San Diego
Prostatic Neoplasms
A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)
The purpose of this study is to compare the improvement in time to prostate specific antigen (PSA) progression (TTPP, as defined by Prostate Cancer Working Group 2 [PCWG2]) of apalutamide versus placebo in Chinese participants…
- Trial name
- NCT04108208
- Testing
- Apalutamide, Androgen-deprivation Therapy (ADT)
- Where
- 27 sites in China
- Volunteers
- 75 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer
PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
Background: The immune system is the cells and organs in the body that recognize and fight infection and cancer. The prostate specific antigen (PSA)/TRICOM (PROSTVAC) vaccine might teach the immune system to find and kill certain…
- Trial name
- NCT02933255
- Testing
- PROSTVAC-V/F, Nivolumab, Prostatectomy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Small Cell Prostate Cancer, Neuroendocrine Prostate Cancer
A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
This study will evaluate the response rate of MLN8237 in patients with histologically confirmed or clinically suspected metastatic neuroendocrine prostate cancer (NEPC).
- Conditions
- Small Cell Prostate Cancer, Neuroendocrine Prostate Cancer, Prostate Adenocarcinoma Plus > 50% Immunohistochemical Staining for Neuroendocrine Markers
- Trial name
- NCT01799278
- Testing
- MLN8237
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- Weill Medical College of Cornell University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.